Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

Acute Myeloid Leukemia

Bob Löwenberg, James R. Downing, Alan K. Burnett · New England Journal of Medicine · 1999 · 1.2K citations

Medicine, Oncology, Radiation Oncology +14

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer et al. · Journal of Clinical Oncology · 2001 · 893 citations

Medicine, Hematology, Pharmacology +17

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

Catherine P. Leith, Kenneth J. Kopecky, John E. Godwin et al. · Blood · 1997 · 868 citations

Medicine, Geriatric Medicine, Oncology +8

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

U. Winkler, Mark A. Jensen, Oliver Manzke et al. · Blood · 1999 · 658 citations

Life Sciences, Hematology, Immunology +17

Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia

Philip R. Hamann, Lois M. Hinman, Irwin Hollander et al. · Bioconjugate Chemistry · 2001 · 587 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17